Introduction: Bypassing agents are required for bleed management in people with haemophilia A and inhibitors (PwHAI) undergoing major surgery, including patients on prophylaxis. In the setting of prophylaxis with emicizumab, recombinant activated factor VII (rFVIIa) is the preferred bleed treatment class for these patients. Eptacog beta is the newest addition in the rFVIIa product class in the US and is approved in the surgical setting in the EU. The aim of this report is to describe the safety, effectiveness, and real-world use of eptacog beta for perioperative bleed control during major surgery in PwHAI in the US using emicizumab prophylaxis.
Methods: This is a retrospective case series describing eight PwHAI on emicizumab prophylaxis who used eptacog beta for perioperative bleed control during major surgery (six arthroplasties, one radical nephrectomy, and one transforaminal lumbar interbody fusion) from five centres in the US. Patient characteristics, medical history, perioperative eptacog beta usage, intraoperative surgical and haemostatic outcomes, and postoperative outcomes are described.
Results: All participants achieved haemostatic control with eptacog beta during major surgery using doses ranging from 70 to 225 µg/kg (median: 76.9 µg/kg). A median of 17 doses (range: 9–77) was used per participant. Participants were treated for a median of 5.75 days (range: 2–29). One case included intraoperative tranexamic acid and thrombin. Four individuals were switched to other haemostatic agents postoperatively due to lack of sufficient eptacog beta stock in the hospital pharmacy. Three participants received eptacog beta for the entirety of the postoperative period. One participant received eptacog alfa pre- and intraoperatively and switched to eptacog beta in the postoperative period. Intraoperatively, there were no adverse bleeding events and no need for transfusions. Postoperatively, there were no bleeds, thromboembolic events, or hospital readmission within 30 days due to bleeding or thrombosis.
Conclusions: Eptacog beta provided adequate haemostatic control during and after major surgical procedures in PwHAI who were on prophylaxis with emicizumab, with no safety signals observed.
Plain Language Summary
People with haemophilia A who develop inhibitors have a higher risk of bleeding, particularly during major surgery. Even when these individuals receive prophylaxis with emicizumab, additional treatments such as bypassing agents are often needed to help control bleeding during and after surgery. Eptacog beta is a newer bypassing agent that has been approved for use in people with haemophilia A and inhibitors. This study reviewed the medical records of eight people with haemophilia A and inhibitors who were receiving emicizumab prophylaxis and underwent major surgery at five treatment centres in the United States. The surgeries included six joint replacement procedures, one kidney removal, and one spinal fusion procedure. All patients received eptacog beta, a recombinant activated factor VII (rFVIIa) bypassing agent, to help control bleeding during and/or after surgery. All eight patients achieved successful bleeding control. No excessive bleeding events occurred during the operations, and no patients required blood transfusions. Following surgery, no bleeding episodes, blood clots, or hospital readmissions related to bleeding or thrombosis within 30 days of surgery were reported. In some cases, patients were switched to alternative treatments after surgery due to limited hospital supply of eptacog beta, and not due to treatment failure. These findings suggest that eptacog beta can provide effective and safe bleeding control during and after major surgery in people with haemophilia A and inhibitors who are receiving emicizumab prophylaxis. Although the study included a small number of patients, the results add to the growing evidence supporting the use of eptacog beta in the surgical setting.